secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2026-02-25T23:59:59+00:00
Accession:  0001193125-26-071674
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia Q4 2025 GAAP revenue $284M; FY25 $1.07B; NUPLAZID $174M, DAYBUE $110M; FY26 guidance $1.22-1.28B
--------------------------------------------------------------------------------

- Q4 2025 GAAP total revenue $284M; non-GAAP adjusted $298M (+16% YoY); FY25 GAAP $1.07B, non-GAAP $1.08B.
- GAAP NUPLAZID net sales $174M (includes $20M IRA rebate adjustment); non-GAAP adjusted $189M, up 17% vs Q4 2024.
- DAYBUE net sales $110M in Q4 (+13% YoY) and $391M for FY25.
- Net income Q4 $274M ($1.60 diluted EPS) including $250M tax benefit; FY net income $391M ($2.30 EPS). Cash & investments $820M.
- FY 2026 guidance: total revenue $1.22-1.28B; NUPLAZID $760-790M; DAYBUE $460-490M; R&D $385-410M; SG&A $660-700M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000119312526071674/0001193125-26-071674-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000119312526071674/acad-20260225.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-071674

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer